Participated · Series A · Mar 2023

Neowise (新景智源生物科技) focuses on the discovery and development of TCR-T immunotherapies aimed at solid tumors. The company has built a proprietary high-throughput, high-sensitivity target-antigen/TCR discovery platform (CAST®) that combines AI computation with experimental validation to rapidly identify high-affinity, tumor-specific TCR sequences. Its lead candidate, NW-101C, targets PRAME and is the first domestic therapy against this antigen to reach clinical trials, currently in a Phase I registration study across multiple late-stage solid tumors. A second candidate, NW-301V, targets the KRAS G12V mutation and delivered an objective response rate of 50% and a disease control rate of 100% in an early trial involving 14 evaluable colorectal and pancreatic cancer patients, with no dose-limiting toxicities observed. Over the past two years the company has advanced two programs into the clinic, validating its platform capabilities. Proceeds from the latest financing will fund further clinical development of these core assets and advance multiple preclinical programs, while supporting commercialization and international expansion efforts. The firm has received continued backing from existing investors alongside new institutional support, underscoring confidence in its pipeline and platform.

Participated · Series C · Aug 2021

商涌科技 builds a one-stop, full-cycle risk-management platform for the commercial health and life insurance market, anchored on a smart underwriting and risk-control engine (新机风控). It operates a claims advance service (新机安付) for inpatient and critical-illness coverage and a health-management platform (新机健康) offering medication access, consultations, chronic-disease management, and follow-up. The company has expanded into single-disease course management and in August 2021 launched a pediatric leukemia product (心守护) covering ages 28 days to 17 years, developed with top medical institutions and specialists. As of the article the firm has served 70+ insurance companies, nearly 500 personal-insurance products and provided risk-control services for about 20 million policy-holder touchpoints. In August 2021 商涌 completed a C round described as an "亿元" financing to deepen health-insurance management and single-disease product development, led by 招商健康 with 远毅资本 participating. The company emphasizes combining underwriting, claims capability and disease-course management to embed new therapy responsibilities into insurance products and to improve long-term survival expectations for clients.

Participated · Series C · Aug 2021

MediTrust is a Shanghai-based private healthcare payor founded in 2017 and led by founder and CEO Seth Zhang. It leverages proprietary integrated platforms to serve healthcare and insurance companies, delivering comprehensive healthcare products and services aimed at lowering medical costs. A core service, Care2Pay, partners with more than 50 pharmaceutical and insurance companies and over 2,000 DTP pharmacies, with national coverage in over 400 cities. Care2Pay enables millions of patients with cancer, chronic, and rare diseases to access innovative drugs more affordably; in the first half of 2021 it helped patients and families save over RMB300 million in healthcare expenditures. MediTrust also collaborates with insurers to launch municipal health insurance products in more than 40 cities, including Beijing and Shanghai, and has been instrumental in Shanghai’s Huhuibao coverage expansion.

Participated · Series B · Aug 2020

Shukun is a Chinese startup that uses AI to power medical imaging diagnosis. The company develops AI-driven tools for diagnosing medical images. It secured 700 million yuan (about $108 million) in a new funding round. The round was led by Goldman Sachs and Primavera Capital Group. The funding was announced on Monday. The article does not provide operating metrics, use of proceeds, or details on other investors. Shukun is a Beijing-based artificial intelligence startup focused on medical diagnostics. Its core product, CoronaryDoc, is an assisting software launched in early 2018 that helps doctors diagnose heart disease using visual recognition technologies. By the end of September 2019 CoronaryDoc had been used on a trial basis in more than 100 hospitals in China. In February the company launched an AI system to help diagnose COVID-19, which has been deployed in multiple hospitals including Wuhan Zhongxin Hospital. Shukun plans to use new funding to expand application of its AI technologies for cardiovascular and neurological diseases and cancer detection across hospitals nationwide, with emphasis on grass‑root medical institutions. The company was founded in 2017.

Led · Equity · Dec 2017

Lion Rock FinTech is a Hong Kong-based fintech company that will own Noble Apex Advisors Ltd., an SFC-licensed firm, upon completion of the transaction. Noble Apex operates iFund, an online fund distribution platform offering over 1,000 mutual funds from more than 50 asset management companies. Lion Rock will also operate lionfin.com, a financial media platform providing real-time financial information and comprehensive wealth management content. The company completed an equity financing of HK$50m (subject to Hong Kong SFC approval) to support its operations and growth. Following the transaction, Dr. Chan Mou-fung, founder of iFund, will serve as Chairman of Lion Rock's Board of Directors. The funding and acquisition position Lion Rock to expand distribution and media services within Hong Kong's wealth-management ecosystem.